Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 19
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Royalty Pharma PLC
RPRX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$60.42
-0.54
-0.88%
Ult. Agg.: Oct 19, 9:30 AM
$60.44
-0.52
-0.85%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Royalty Pharma Financials
Royalty Pharma (RPRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06 per share from the
Benzinga Newsdesk
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of $1.16 per share from the
Benzinga Newsdesk
Earnings Scheduled For February 11, 2026
Benzinga Insights
